|
Outcome
|
No. of studies
|
No. of patients
|
OR (95% CI)
|
P Value
|
I2%
|
Effects model
|
|---|
|
Clinical failure
|
5
|
778
|
0.56 (0.37–0.85)
|
0.12
|
44.9
|
Fixed
|
|
Recurrence of bacteremia
|
8
|
4017
|
1.12 (0.94–1.34)
|
0.80
|
0
|
Fixed
|
|
AEs
|
5
|
672
|
0.37 (0.10–1.41)
|
0
|
83.1
|
Random
|
|
Hepatotoxicity
|
4
|
645
|
0.12 (0.04–0.41)
|
0.51
|
0
|
Fixed
|
|
Nephrotoxicity
|
3
|
484
|
0.36 (0.16–0.81)
|
0.88
|
0
|
Fixed
|
|
Anaphylaxis
|
5
|
672
|
0.91 (0.36–2.99)
|
0.53
|
0
|
Fixed
|
|
Hematotoxicity
|
4
|
511
|
0.56 (0.17–1.88)
|
0.42
|
0
|
Fixed
|
|
Discontinuation due to AEs
|
3
|
468
|
0.24 (0.12–0.48)
|
0.30
|
18
|
Fixed
|
- AEs adverse effects, CI confidence interval, OR odds ratio
